



SHL/SEC/
11.08.2016

To,
The Manager,
Bombay Stock Exchange Ltd.
Dept. of Corporate Service
P J Towers, Dalal Street,
Mumbai-400001

Scrip Code: - 537253

Sub: Submission of Un-audited Financial Result for the quarter ended 30.06.2016 under Regulation 30 & 33 of SEBI (Listing Regulation and Disclosure Requirement) Regulation, 2015

Dear Sir,

Please find enclosed herewith the Un- audited Financial Result for the quarter ended 30.06.2016 in Compliance of Regulation 30 read with 33 of SEBI (Listing Regulation and Disclosure Requirement) Regulation, 2015 duly approved by the Board of Directors of the Company in their meeting held on Thursday, 11th August, 2016 alongwith Limited Review Report. The meeting was commencement at 3.30 P.M. and concluded at 6.25 P.M.

The Company does not have any subsidiary Company, hence the results submitted is the standalone results only.

It is further declared that there are no qualification made by the Statutory Auditory of the Company.

Kindly take the same on record.

Thanking you.

Your Faithfully
For Sunil Healthcare Limited


Pawan Rathi
CFO



CC- Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata- 700 001

Sunil Healthcare Limited

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049
T: +91 11 49435555/00 F: +91 11 43850087 e-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com
CIN No. L24302DL1973PLC189662

Singhi & Co.

Chartered Accountants

402-403, Pragati House, 47-48, Nehru Place, New Delhi-110 019 (India) Ph. : (011) 30820179, 30820180, 41018091
e-mail : newdelhi@singhico.com Website : www.singhico.com

Limited Review Report

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited financial results of Sunil Healthcare Limited for the quarter ended 30th June'2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co,
Chartered Accountants
Firm Registration No. 302049E



Place : New Delhi
Date: 11th August '2016


B.K. Sipani
Partner
Membership No. 088926

KOLKATA

MUMBAI

CHENNAI

BENGALURU

AHMEDABAD

**SUNIL HEALTHCARE LIMITED**

Registered Office

38E/252-A, Vijay Tower, Shahpurjat
New Delhi-110049

Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com

CIN : L24302DL1973PLC189662

Unaudited Financial Results

for the quarter ended 30th June 2016

₹ in Lakhs

	Particulars	Quarter Ended			Year Ended
		30th June 2016	31st March 2016	30th June 2015	31st March 2016
		Unaudited	Ref. to Note no. 4	Unaudited	Audited
1	Income from Operations				
	a) Net Sales/Income from Operations (Net of Excise duty)	2,095.48	2,276.62	1,632.06	8,091.29
	b) Other Operating Income	18.10	10.82	24.71	71.08
	Total Income from operation (net)	2,113.58	2,287.44	1,656.77	8,162.37
2	Expenses				
	a) Cost of Materials consumed	786.16	764.25	624.27	2,776.42
	b) Purchase of Stock-in-trade	-	421.68	0.05	1,016.43
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	143.13	(70.92)	(115.52)	(260.33)
	d) Employees benefit expenses	249.02	244.10	227.07	941.75
	e) Depreciation and amortisation expenses	104.07	112.27	90.21	381.95
	f) Other Expenses	518.63	611.77	516.65	2,254.35
	Total Expenses	1,801.01	2,083.15	1,342.73	7,110.57
3	Profit from operation before Other Income, finance costs and exceptional items	312.57	204.29	314.04	1,051.80
4	Other Income	33.19	74.16	19.08	132.55
5	Profit from ordinary activities before finance costs and exceptional items	345.76	278.45	333.12	1,184.35
6	Finance costs	99.00	95.06	84.86	381.30
7	Profit from ordinary activities after finance costs but before exceptional items	246.76	183.39	248.26	803.05
8	Exceptional Items	-	-	-	-
9	Profit from ordinary activities before tax	246.76	183.39	248.26	803.05
10	Tax Expenses (Net)	91.84	60.52	102.69	280.53
	a) Deferred Tax	4.58	33.80	6.19	146.98
	b) Income Tax	87.26	26.72	96.50	133.55
11	Net Profit from ordinary activities after tax	154.92	122.87	145.57	522.52
12	Extraordinary Items (net of tax expenses)	-	-	-	-
13	Net Profit for the period	154.92	122.87	145.57	522.52
14	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates	154.92	122.87	145.57	522.52
15	Paid-up equity share capital (Face value per share ₹10/-)	1,025.48	1,025.48	1,025.48	1,025.48
16	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				2,080.56
17	Earning per share of (before & after extraordinary items) ₹10/- each(not annualised)				
	(a) Basic (₹)	1.51	1.20	1.42	5.10
	(b) Diluted (₹)	1.51	1.20	1.42	5.10



Segment wise Revenue, Results and Capital Employed for the Quarter ended on 30th June 2016.

₹ in Lakhs

	Segment wise Performance	Quarter Ended			Year Ended
		30th June 2016	31st March 2016	30th June 2015	31st March 2016
		Unaudited	Ref. to Note no. 4	Unaudited	(Audited)
1	Segment Revenue				
	Capsules	2,113.58	1,760.18	1,656.77	7,208.23
	Marketing of Food Products	-	527.26	-	954.14
	Total Income From Operations (Net)	2,113.58	2,287.44	1,656.77	8,162.37
2	Segment Results				
	Capsules	335.65	187.97	321.18	1,056.89
	Marketing of Food Products	(10.14)	73.00	(4.83)	50.52
	Profit/(Loss) Before Finance Cost & Tax	325.51	260.97	316.35	1,107.41
	Less: Finance Cost	99.00	95.06	84.86	381.30
	Add: Un-allocable Expenses / (Income)(Net)	20.25	17.48	16.77	76.94
	Profit/(Loss) Before Tax	246.76	183.39	248.26	803.05
3	Capital Employed(Segment Assets - Segment Liabilities)				
	Capsules	7,137.39	5,605.84	5,237.49	5,605.84
	Marketing of Food Products	147.26	160.75	86.39	160.75
	Total	7,284.65	5,766.59	5,323.88	5,766.59
	Segment Assets				
	Capsules	8,534.36	8,274.65	6,439.04	8,274.65
	Marketing of Food Products	166.87	175.76	86.42	175.76
	Unallocated Assets	222.32	303.91	210.34	303.91
	Total	8,923.55	8,754.32	6,735.80	8,754.32
	Segment Liabilities				
	Capsules	1,396.97	2,668.81	1,201.55	2,668.81
	Marketing of Food Products	19.60	15.01	0.03	15.01
	Unallocated Liabilities	780.89	607.54	630.02	2,803.71
	Total	2,197.46	3,291.36	1,831.60	5,487.53

Notes:

- 1 Previous period figures have been regrouped, wherever found necessary.
- 2 Expansion of capacity for manufacturing of Empty Hard Gelatin Capsule up to 11 billion p.a. (approx) is under implementation and expected to be commissioned by September 2016.
- 3 No investor complaint was received during the quarter ended 30.06.2016 and there was no complaints pending as on 30.06.2016
- 4 Figures of the corresponding previous period/ year have been regrouped/ rearranged wherever necessary, to make them comparable. The figures of the quarter ended March 31, 2016 are the balancing figures between audited figures in respect of the full financial year ended on 31.03.2016 and the reviewed published year to date figures upto December 31, 2015.
- 5 The above financial results have been reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 11th August 2016.

Place : New Delhi
Date : 11.08.2016

For & On Behalf of the Board
Anil Khanna
Chairman Cum Managing Director
DIN 00759951

